Dual-listed diagnostics company Pacific Edge is lauding the publication of new clinical evidence which it says shows significant improvements in its Cxbladder tests.
The company today announced that a study of 804 patients had found that adding DNA biomarkers to its Cxbladder Triage (CxbT) and
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
